Title of article
ZNF423 Is Critically Required for Retinoic Acid-Induced Differentiation and Is a Marker of Neuroblastoma Outcome
Author/Authors
Huang، نويسنده , , Sidong and Laoukili، نويسنده , , Jamila and Epping، نويسنده , , Mirjam T. and Koster، نويسنده , , Jan and Hِlzel، نويسنده , , Michael A. Westerman، نويسنده , , Bart A. and Nijkamp، نويسنده , , Wouter and Hata، نويسنده , , Akiko and Asgharzadeh، نويسنده , , Shahab and Seeger، نويسنده , , Robert C. and Versteeg، نويسنده , , Rogier and Beijersbergen، نويسنده , , Roderick L. and Bernards، نويسنده , , René، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2009
Pages
13
From page
328
To page
340
Abstract
Summary
ids play key roles in differentiation, growth arrest, and apoptosis and are increasingly being used in the clinic for the treatment of a variety of cancers, including neuroblastoma. Here, using a large-scale RNA interference-based genetic screen, we identify ZNF423 (also known as Ebfaz, OAZ, or Zfp423) as a component critically required for retinoic acid (RA)-induced differentiation. ZNF423 associates with the RARα/RXRα nuclear receptor complex and is essential for transactivation in response to retinoids. Downregulation of ZNF423 expression by RNA interference in neuroblastoma cells results in a growth advantage and resistance to RA-induced differentiation, whereas overexpression of ZNF423 leads to growth inhibition and enhanced differentiation. Finally, we show that low ZNF423 expression is associated with poor disease outcome in neuroblastoma patients.
Keywords
CELLCYCLE
Journal title
Cancer Cell
Serial Year
2009
Journal title
Cancer Cell
Record number
1336962
Link To Document